Clinical Trials Browser

Phase 2 × Hearing Loss × 90 days × Clear all

NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Withdrawn

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss